Tempus AI rises after partnering with Daiichi Sankyo for cancer drug

Shares of genetics-testing firm Tempus AI TEM.O rise 2% to $49.34 premarket

Co says it partnered with Japan's Daiichi Sankyo to use AI to speedily develop a drug for cancer

Deal centers on an antibody drug conjugate, a targeted treatment that delivers chemotherapy directly to tumour cells

Tempus says it will use AI tools and large real-world patient data to find biomarkers – biological signals that show which patients may benefit

Adds the companies will jointly build AI models to select patients for trials and better understand how different patients respond to the drug

Financial terms of the partnership not disclosed

TEM shares up ~75% in 2025